Wednesday, November 14, 2018
Enable Injections, Inc., a patient-centric drug delivery combination product company developing advanced wearable devices for subcutaneous delivery of high-volume therapeutics, today announced it has entered into development agreements with Apellis Pharmaceuticals, and most recently, UCB. Enable Injections currently has partnerships with five companies to deliver products that shift treatment to the home with easy, convenient self-administration of new large-volume drugs.
The rapidly growing pipeline of large-volume therapeutics, with thousands in development, is comprised of a range of products, many first-in-class. Of these, monoclonal antibodies (mAbs) account for 50% of the top 100 drugs and are projected to maintain their dominant position in treating a broad range of diseases including various cancers, autoimmune disorders, and genetic diseases.
Enable Injections' enFuse™ body-worn delivery platform overcomes the barriers to delivering viscous, concentrated, large-molecule formulations. enFuse is the preferred option for pharmaceutical companies seeking to differentiate their products with more convenient subcutaneous administration of large 5 mL to 50 mL doses that can replace more costly intravenous infusions necessitating a trip to a healthcare facility.
"Because enFuse frees patients to self-administer at home, it greatly enhances patient experience and overall patient value," said Jeff Wren, UCB's Head, Neurology Patient Value Unit. "enFuse is the right answer for patient needs, which makes it a great addition to our program."
"We are conducting human clinical trials using the enFuse technology to deliver our novel complement immunotherapies subcutaneously," Cedric Francois, MD, PhD, Co-Founder and CEO of Apellis Pharmaceuticals said. "With our broad therapeutic application, we are excited to partner with Enable to bring promising new therapies with a more patient-centric drug delivery system to patients in need."
Patient feedback on their treatment experience will be considered by regulatory agencies when the appropriate data is collated. For patients with chronic and often asymptomatic conditions, it is often the delivery, not the drug, that defines their experience and adherence to ongoing therapy.
"Pharmaceutical companies racing to improve outcomes and be recognized as patient-centric are realizing the symbiosis between drug and delivery," said Michael D. Hooven, Enable Injections' President and CEO. "They are partnering with Enable Injections to improve the patient experience, with the aim of increasing adherence and achieving the outcomes necessary for commercial success."